MorningSignal
Research Platform
2026-04-11 21:47
A light earnings day with three US-listed companies near or above the $2B market cap threshold reporting: BlackBerry (BB) delivered the standout print with a decisive double-beat on Q4 FY2026, declaring its multi-year turnaround complete and sending shares up ~10% after hours. WD-40 (WDFC) posted mixed results—revenue beat handily (+11% YoY) but EPS missed on a one-time tax comp, with the stock flat after hours as guidance underwhelmed. Neogen (NEOG), at the $2B borderline, beat on both lines but sold off ~6% pre-market on Animal Safety segment weakness. Below the $2B threshold but too notable to ignore, Simply Good Foods (SMPL) cratered 12-15% after a disastrous quarter featuring a $249M impairment charge and a CEO who publicly called his own performance "unsatisfactory."
BB — BUY the breakout. Turnaround declared complete. Record QNX revenue, $950M royalty backlog, FY27 guidance implying 15% top-line growth at the high end. The stock at ~$3.50-3.80 is still pricing this as a broken story, not a growth company. Conviction: High.
WDFC — HOLD, trim into strength. Revenue growth is real (11% consolidated, 13% maintenance products) but EPS guidance of $5.75-6.15 for FY26 implies margin compression ahead. At ~22x forward earnings for a single-product company, the risk/reward is neutral. Conviction: Medium.
SMPL — Avoid / potential short. GLP-1 disruption is real and accelerating. The Atkins brand is in structural decline. CEO's candor is appreciated but the turnaround plan (rebrand as fiber/protein, cut costs) is a 12-18 month execution story with no near-term catalyst. Wait for evidence of stabilization. Conviction: High (bearish).
| Metric | Actual | Consensus | Beat/Miss |
|---|---|---|---|
| Q4 Adj. EPS | $0.06 | $0.04-0.05 | Beat by 20-50% |
| Q4 Revenue | $156.0M | $144.4M | Beat by 8.0% |
| FY26 Revenue | $549.1M | $540.8M | Beat by 1.5% |
| FY26 Adj. Basic EPS | $0.16 | $0.09 | Beat by 78% |
Quality of the beat: Organic and high-quality. Q4 revenue up 10% YoY driven by QNX record performance. GAAP net income swung to $24.3M profit from a loss position. Adj. EBITDA of $36.1M represents a 23% margin. Full-year GAAP net income of $53.2M vs. a $79.0M loss in FY25 — a $132M swing.
FY27 Guidance: - Revenue: $584M–$611M (6.4%–11.3% growth vs. FY26's $549M) - Adj. EBITDA: $110M–$130M (implying 19-21% margins, expansion from ~15% in FY26) - Non-GAAP EPS: $0.15–$0.19 - Operating cash flow: ~$100M
Assessment: Guidance is constructive but not aggressive. The high end of revenue guidance ($611M) implies ~15% growth which would be an acceleration from FY26's 3% growth. The EBITDA range implies meaningful margin expansion. Management is sandbagging the low end to build credibility — this is smart capital allocation of investor expectations after years of disappointment.
Management confidence was notably elevated versus prior quarters. CEO declared the multi-year turnaround "complete" — transitioning the narrative from restructuring to "sustained growth story." This is a significant rhetorical shift that signals management believes the business has reached an inflection point.
Key language: Management emphasized a "competitive moat" based on deterministic software performance, critical for safety-regulated environments where AI-driven probabilistic outputs are insufficient. They described QNX automotive safety certifications as a "blueprint" to capture the emerging physical AI and robotics markets.
Conspicuous shift: Prior quarters featured hedging language around "progress" and "transition." This quarter's prepared remarks were definitively forward-looking, with language around "acceleration" and "sustained growth."
Analysts pressed on: - QNX royalty backlog sustainability — $950M provides multi-year visibility; management expressed high confidence in conversion rates. - Physical AI / robotics opportunity — Management pitched this as the next growth vector beyond automotive, leveraging existing safety certifications. - Secure Communications recovery — DBNRR at 94% still below 100%, but management noted improving pipeline and new customer wins.
Positioning: Buy the breakout. This is the quarter where BB transitions from "show me" to "believe me."
Conviction: HIGH
Key risk: QNX growth is tied to automotive production volumes, which face potential tariff/macro headwinds. If auto production softens, the royalty revenue stream could decelerate.
Catalyst timeline: FY27 Q1 results (likely July 2026) — need to see the acceleration confirmed in the first quarter under the new "growth phase" narrative.
One sentence for the PM: BlackBerry just printed its best quarter in years, declared the turnaround complete, and guided for acceleration — at $3.50/share and a $2B market cap, the risk/reward is compelling if QNX momentum holds.
| Metric | Actual | Consensus | Beat/Miss |
|---|---|---|---|
| Q2 FY26 EPS | $1.32 | $1.40 | Miss by 5.7% |
| Q2 FY26 Revenue | $161.7M | $154.9M | Beat by 4.4% |
| Adj. EBITDA | $31.6M | $28.6M | Beat by 10.6% |
Quality of the result: Revenue beat was genuine — consolidated net sales up 11% YoY, driven by 13% growth in maintenance products (the core WD-40 Multi-Use Product franchise). Gross margin expanded 100bps YoY to 55.6%. The EPS miss was driven by the absence of a non-recurring tax benefit from the prior year period ($29.6M prior year net income included a one-time tax item vs. $20.3M this quarter). Adjusting for the tax comp, the underlying business performed well.
FY26 Full-Year Guidance: - Revenue: $630M–$655M (midpoint $642.5M) — reconfirmed - EPS: $5.75–$6.15
Assessment: Guidance was reconfirmed rather than raised, which disappointed given the strong Q2 revenue beat. The EPS range of $5.75-6.15 implies potential margin compression in H2 FY26 despite the gross margin improvement. Management may be building in tariff/input cost buffers. The Street was likely looking for a raise given the top-line momentum.
Management tone was confident on the top line but measured on the outlook. The revenue outperformance was attributed to both volume and pricing gains. However, management noted ongoing exposure to cost volatility, tariffs, and inflationary pressures affecting margins and input costs — suggesting the decision not to raise guidance was deliberate risk management rather than a deterioration signal.
The company positioned itself as resilient through economic cycles given the essential/consumable nature of its products.
Analysts likely pressed on: - Why no guidance raise given the Q2 revenue beat — management likely cited tariff uncertainty and H2 cost assumptions. - Tariff exposure — WD-40 manufactures and sells globally, with meaningful exposure to trade policy shifts. - Pricing power sustainability — whether the 11% revenue growth includes meaningful pricing that could face consumer pushback.
Positioning: Hold. The underlying business is performing well, but at the current valuation (~22x forward), you need guidance raises to drive the stock higher, and management isn't providing them.
Conviction: MEDIUM
Key risk: Tariff escalation on specialty chemicals or finished goods could compress margins in H2. Currency headwinds from strong USD.
Catalyst timeline: Q3 FY26 results (likely July 2026) — need to see if management raises guidance as tariff/cost visibility improves.
One sentence for the PM: WD-40 delivered strong revenue growth but the lack of a guidance raise at a premium valuation keeps us on the sideline — the business is fine but the stock needs a catalyst.
Note: NEOG market cap is borderline at ~$2.0-2.1B. Including due to institutional relevance in food safety/animal health.
| Metric | Actual | Consensus | Beat/Miss |
|---|---|---|---|
| Q3 FY26 Adj. EPS | $0.09 | $0.06 | Beat by 50% |
| Q3 FY26 Revenue | $211.2M | ~$204.6M | Beat by 3.2% |
| Adj. EBITDA Margin | 22.8% | N/A | Near-record level |
Quality of the beat: Mixed. The EPS beat was significant (50% above consensus), but the top line was only modestly ahead. The real story is in the segment divergence: Food Safety was strong while Animal Safety was a significant drag.
GAAP: Net loss of $17.0M ($(0.08)/share) due to non-cash items. Adjusted Net Income of $19.4M paints a much cleaner picture.
Assessment: The revenue raise is a positive signal, but keeping EBITDA flat suggests mix shift toward lower-margin revenue. The Genomics divestiture is a portfolio simplification move — management is shedding a non-core business to focus on Food Safety and Animal Safety. This is strategically sound but creates near-term noise.
Management struck a balanced but cautious tone. Confidence was evident in the Food Safety segment's trajectory and margin performance, but there was clear acknowledgment that Animal Safety supply chain issues are a meaningful headwind. Management positioned the Genomics divestiture as a "sharpening the portfolio" move rather than a fire sale.
Analysts pressed hardest on: - Animal Safety timeline to recovery — when will supply chain disruptions normalize? - Genomics divestiture rationale and proceeds use — likely debt paydown and/or reinvestment in Food Safety. - Food Safety durability — whether the 4% core growth is sustainable and can accelerate.
Positioning: Hold / slight underweight. The Food Safety business is solid, but consolidated growth at 0.1% doesn't justify a premium multiple. Wait for Animal Safety recovery evidence.
Conviction: LOW
Key risk: Animal Safety disruptions extend beyond FY26, creating a multi-quarter drag. Genomics divestiture creates revenue cliff.
Catalyst timeline: Q4 FY26 results (likely July 2026) — need to see Animal Safety inflect and evidence of Genomics proceeds deployment.
One sentence for the PM: Neogen's Food Safety franchise is best-in-class but the Animal Safety drag and portfolio complexity make this a "show me" story — stay patient until consolidated growth inflects.
Included for PM awareness given the severity of the print and sector read-through for consumer staples/GLP-1 disruption.
| Metric | Actual | Consensus | Beat/Miss |
|---|---|---|---|
| Q2 FY26 Net Sales | $326.0M | ~$345M | Miss by 5.5% |
| Q2 FY26 Adj. Diluted EPS | $0.84 | $0.95 est. | Miss by ~11.6% |
| Q2 FY26 GAAP EPS | $0.45 | $0.40 | Beat (but misleading — massive impairment) |
| Adj. EBITDA | $55.5M | N/A | Down 18.4% YoY |
| GAAP Net Loss | $(159.7M) | N/A | vs. $36.7M profit YoY |
Quality of the miss: Terrible. Net sales down 9.4% YoY. Adjusted EBITDA down 18.4% YoY. The company took a $249M aggregate non-cash impairment charge on Atkins ($62M) and OWYN ($187M) brand intangible assets. This is management formally admitting these brands are worth significantly less than what was paid for them.
This is a significant guidance cut that signals the problems are not temporary.
CEO Joe Scalzo's opening was remarkably candid: "I want to make it quite clear that we are not satisfied with our current performance." This level of CEO self-criticism is rare and signals the depth of the problem. Management outlined a pivot strategy: rebrand Atkins emphasizing fiber and muscle-preserving protein levels, moving away from the 1990s-era "low carb" identity. They also announced a major cost restructuring covering staffing, agencies, manufacturing, and logistics.
What they DIDN'T say: Management did not quantify the GLP-1 headwind or provide data on how many Atkins consumers are switching to GLP-1 medications. This omission is conspicuous.
Positioning: AVOID / short candidate on rallies.
Conviction: HIGH (bearish)
Key risk to bearish thesis: Successful Atkins rebrand or GLP-1 tailwind eventually materializes as post-GLP-1 consumers seek protein-rich foods. But this is a 12-18 month story at best.
One sentence for the PM: Simply Good Foods is a poster child for GLP-1 disruption in consumer staples — the $249M impairment is management waving the white flag, and the turnaround plan lacks near-term catalysts.
1. Tariff Uncertainty Looming: WD-40 explicitly cited tariff/cost volatility as reason for not raising guidance despite a strong quarter. This echoes broader market concern heading into Q1 2026 earnings season proper next week.
2. Software/IP Businesses Outperforming: BlackBerry's QNX royalty model (recurring, high-margin, growing 20% YoY) is the standout business model this earnings day. Asset-light, IP-driven revenue streams continue to command premium valuations.
3. GLP-1 Disruption — Second-Order Effects Materializing: Simply Good Foods' impairment is a concrete data point that GLP-1 medications are disrupting adjacent categories (snack bars, meal replacements, weight-management foods) more aggressively than expected. PMs with consumer staples exposure should audit portfolios for GLP-1 vulnerability.
4. Beat-and-Sell Pattern in Small/Mid-Caps: Neogen beat on both lines and still sold off 6%. This is consistent with a risk-off sentiment in smaller-cap names where investors are demanding not just beats but clear growth acceleration narratives.
No BMO catch-up names identified for today. The April 9, 2026 earnings slate was primarily AMC-focused, with BlackBerry reporting after market close and the others reporting around the close/after hours. No prior-day BMO names had pending transcript catch-ups from the morning briefing cycle.
No significant large-cap BMO reporters scheduled for Friday, April 10, 2026.
The real action begins Tuesday, April 14, 2026 when Q1 2026 earnings season kicks off in earnest:
PM Preparation Note: Next week's bank earnings will set the tone for Q1 2026 earnings season. Key themes to watch: net interest income trajectory, credit quality (consumer + commercial), trading revenue, and management commentary on tariff/recession risk.
Report compiled: April 9, 2026, Evening Analyst: AI Equity Research Next scheduled briefing: April 10, 2026, 8:00 AM ET (BMO Preview)